Sarepta Therapeutics (SRPT) Total Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• On a quarterly basis, Total Liabilities fell 27.93% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 27.93% decrease from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 9.29% from the prior year.
• Total Liabilities slipped to $1.7 billion in Q1 2026 per SRPT's latest filing, from $2.2 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $2.7 billion in Q4 2022 and bottomed at $1.7 billion in Q1 2026.
• The 5-year median for Total Liabilities is $2.3 billion (2023), against an average of $2.3 billion.
• Across the five-year window, Total Liabilities rose 24.29% in 2022 and decreased 27.93% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $2.7 billion in 2022, then dropped by 12.33% to $2.4 billion in 2023, then advanced by 1.26% to $2.4 billion in 2024, then retreated by 9.29% to $2.2 billion in 2025, then declined by 24.23% to $1.7 billion in 2026.
• Per Business Quant, the three latest SRPT Total Liabilities figures stand at $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.2 billion (Q3 2025).